4Q-25 Quarterly Results 4Q-25 Revenue of $642M, 0% y/y 4Q-25 Net loss per share of $(0.14)(1) 4Q-25 Adj. EBITDA(2) of $83.8M, 12% y/y FY-26 Revenue outlook range of $2,470M to $2,587M Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limit ...

Core Viewpoint - Hims & Hers Health Inc's stock plummeted 12.6% after the FDA issued a warning regarding the sale of unapproved compounded GLP-1 drugs, indicating a significant regulatory challenge for the company [1]. Regulatory Actions - The FDA is taking decisive actions against companies like Hims & Hers that sell compounded drugs as alternatives to approved treatments, aiming to protect consumers from unverified products [3]. - The FDA's intervention follows Hims & Hers' aggressive expansion, including the launch of a compounded semaglutide tablet priced at $49 per month, which the company claims is designed to enhance absorption [3]. - The FDA has warned that companies cannot claim unapproved compounded products are equivalent to FDA-approved drugs, indicating a tightening of regulations [3]. Competitive Landscape - Novo Nordisk, the manufacturer of the popular drug Wegovy, has responded by labeling Hims & Hers' new product as "unapproved, misleading, and untested," and plans to take legal and regulatory action against the company for "illegal mass compounding" [3]. - Novo Nordisk emphasizes that it remains the only manufacturer producing a legally approved oral semaglutide tablet using proprietary absorption technology [3]. Company Positioning - Hims & Hers executives argue that their platform provides essential accessibility and personalized services for patients who prefer non-injection methods [4]. - The company claims to have invested years in building the necessary infrastructure to offer personalized options to patients [4]. - The FDA's recent stance indicates an escalation in actions against misleading direct-to-consumer advertising, following previous warnings about unverified claims regarding compounded drugs [4]. Market Implications - The regulatory crackdown creates a volatile environment for telehealth investors, as Hims & Hers faces significant survival threats since its inception [5]. - The market is closely monitoring whether the FDA will follow through on its threats of legal action without prior notice, which could impact Hims & Hers' promised affordability [5].

Core Viewpoint - Company expects a net profit loss of 25 million to 36 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 25 million to 36 million yuan for 2025 [1] - The forecasted loss is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to a decrease in product procurement prices and fluctuations in order volumes, which pose challenges to sales revenue and gross margin [2] - Despite cost-saving measures, fixed expenditures remain constant, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is adjusting its business layout and strategy, focusing on the "ACME" proprietary products, increasing R&D investment, and expanding the market development team to enhance high-value services for hospital clients [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to shareholders was -12.39 million yuan, a decline of 146.65% year-on-year [3] - The gross margin was reported at 15.84%, with a debt ratio of 27.18% [3]

Core Viewpoint - BFB HEALTH, formerly known as 财讯传媒集团, has officially rebranded as "BFB HEALTH," marking its position as the first publicly listed company in China's remote medical health management sector, with a market capitalization exceeding 1.2 billion HKD [1][3] Group 1: Company Overview - The rebranding ceremony took place in Bozhou, Anhui, which is recognized as the "World Capital of Traditional Chinese Medicine" [1] - BFB HEALTH's stock closed at 0.99 HKD, indicating strong market interest and confidence in the company's future [1] - The company plans to allocate 50% of its secondary market financing towards AI upgrades and new drug development, while the other 50% will focus on product iteration, brand building, and upgrading intelligent production lines [1][5] Group 2: Market Context - The National Healthcare Security Administration issued guidelines for remote surgical assistance pricing, paving the way for the commercialization of remote medical services [3] - The remote medical market in China has surpassed 100 billion CNY, with a compound annual growth rate of over 25% [8] - BFB HEALTH fills a gap in the market as the first dedicated player in the remote medical sector on the Hong Kong stock exchange, leveraging its regional advantages in traditional Chinese medicine [3][4] Group 3: Business Model and Strategy - BFB HEALTH's business model mirrors that of U.S. telehealth giant Hims & Hers, focusing on a closed-loop system of online diagnosis, product services, and health management [4] - The company employs a "1+N" strategy, utilizing a cross-border drug purchasing platform to support multiple independent brands, thereby addressing diverse health needs and creating competitive advantages [5] - BFB HEALTH aims to enhance user engagement through a subscription model, similar to Hims, which locks in long-term users and stabilizes cash flow [4] Group 4: Industry Impact - BFB HEALTH is set to drive digital transformation in the healthcare industry by utilizing digital channels and AI technology, thus improving service efficiency and accessibility [6] - The company promotes personalized health services, shifting the industry focus from product-driven to user-centered approaches [6] - As the first private enterprise listed in Bozhou, BFB HEALTH is expected to stimulate local economic growth and attract related businesses, enhancing the regional healthcare ecosystem [7]

Group 1 - BFB Health Limited, formerly known as 财讯传媒集团有限公司, officially changed its name on January 22, 2023, and aims to become the "first stock of remote medical health management in China" [1] - The company is based in Bozhou and is the first private enterprise listed in the region, leveraging local resources to grow into a national remote medical service platform [3] - The Chinese remote medical market is projected to exceed 100 billion yuan by 2025, with a compound annual growth rate of over 25%, positioning BFB Health as a leading player in the industry [3] Group 2 - BFB Health plans to allocate 50% of its secondary market financing to AI upgrades in the health industry and new drug development, while the other 50% will focus on product iteration, brand building, and upgrading intelligent production lines [3] - The company is driving digital transformation in the industry through online consultations and AI technology, enhancing service efficiency and coverage [4] - BFB Health is leading the trend of personalized health services by utilizing big data and AI to analyze user health needs, shifting the industry from a product-oriented to a user-oriented approach [4] Group 3 - The company is fostering regional industrial collaboration by enhancing the local supply chain, including traditional Chinese medicine cultivation and logistics, thereby attracting related enterprises to Bozhou [5] - BFB Health's development is expected to create numerous job opportunities, increase local tax revenue, and contribute to regional GDP growth [5] - The company aims to optimize service experiences through technological advancements, making online consultations more convenient and allowing users in remote areas to access quality medical services [5] Group 4 - Under the "Healthy China" strategy, remote medical services are seen as a core direction for digital transformation in healthcare, with significant future growth potential [5] - BFB Health, as an industry pioneer, is expected to continue deepening technological and model innovations, driving high-quality development in the sector [5]

Core Viewpoint - The National Healthcare Security Administration of China is promoting the large-scale application of surgical robotic arms by establishing a new pricing project for "remote surgical assistance" to enhance the integration of advanced medical technologies into healthcare services [1][2]. Group 1: Pricing Guidelines and Projects - The National Healthcare Security Administration has accelerated the compilation and issuance of medical service pricing project guidelines, having released a total of 36 batches, with provinces averaging 30 batches implemented [1]. - The 37th batch of guidelines includes 37 pricing projects specifically for surgical and treatment assistance operations, along with 5 additional charge items and 1 expansion item, covering key technologies such as 3D printing, intraoperative guidance, and surgical robotic arms [1][2]. Group 2: Focus on Surgical Robots - The pricing guidelines focus on the participation level of surgical robots in operations and their clinical value in precision surgery, categorizing pricing into navigation, execution participation, and precision execution [2]. - A coefficient-based charging model is implemented, allowing surgical robots with higher participation, comprehensive functions, and precise execution to receive higher fee coefficients [2]. Group 3: Remote Surgery and Resource Allocation - The establishment of the "remote surgical assistance fee" pricing project aims to facilitate remote surgeries conducted by experts in resource-rich areas for patients in other regions, thereby reducing the burden of travel for patients seeking quality medical care [2]. - The National Healthcare Security Administration is closely monitoring innovations in the medical industry and has unified over a hundred prospective pricing projects related to new technologies and products, paving the way for gradual industrial upgrades and leading healthcare payment innovations [2].

Core Insights - The company is focusing on smart healthcare, which is a key area supported by national policy [1] - The company collaborates with top research universities and medical institutions to develop clinical diagnostic assistance systems using AI and big data [1] - The company is actively seeking hospital partnerships for practical application of its systems and plans to continuously optimize based on feedback [1] Industry Developments - The national health commission is promoting the development of intelligent healthcare, providing a broad growth space for the industry [1] - The aging population and uneven distribution of medical resources highlight the need for AI-assisted diagnosis and remote medical services [1] - The company is committed to enhancing grassroots medical service capabilities through technology and service integration [1]

Core Insights - Jiangsu Cancer Hospital and Huai'an Cancer Hospital successfully performed two remote surgeries using 5G robotic technology, allowing local patients to access high-quality medical resources without leaving their city [1][2] Group 1: Remote Surgery Implementation - The first surgery involved the removal of two kidney lesions, completed in about one hour with no operational delays, providing a seamless experience similar to traditional robotic surgeries [2] - The second surgery focused on the removal of multiple lung nodules, with the largest nodule measuring approximately 1.5 centimeters, and was completed in about 30 minutes [2] Group 2: Training and Collaboration - Jiangsu Cancer Hospital has been providing ongoing support to Huai'an Cancer Hospital through management and expert teams, enhancing local medical capabilities over the past three years [3] - A systematic support plan was established to ensure the safety of remote surgeries, including advanced equipment and hands-on training for local medical staff [3] Group 3: Future Developments - Jiangsu Cancer Hospital has been approved as a national training base for AI-assisted treatment technologies, aiming to integrate AI deeply into cancer diagnosis and treatment [3][4] - Future developments in robotic surgery will focus on remote medical services and automated surgeries, with plans to implement "one-to-many" and "many-to-one" models for enhanced resource utilization [4]

Group 1: Economic Overview - In 2024, China's GDP exceeded 134.9 trillion yuan, growing by 5.0% year-on-year, ranking among the top major economies globally [2] - The economic structure continues to optimize, with the primary, secondary, and tertiary industries accounting for 6.8%, 36.5%, and 56.7% of GDP, respectively [2] - Consumption, investment, and net exports contributed 2.2, 1.3, and 1.5 percentage points to GDP growth, respectively [2] Group 2: Technological Advancements - China has made significant breakthroughs in cutting-edge technologies such as 6G communication, AI large models, and quantum computing [3] - The first international 6G field test network was established in July 2024, demonstrating potential 6G transmission capabilities [3] - China ranks second globally in the number of open-source participants, with rapid growth in the sector [3] Group 3: New Energy and Carbon Neutrality - The new energy sector has become a growth engine, with China accounting for over 60% of global new wind and solar installations in 2024 [4] - The installed capacity of new energy storage exceeded 70 million kilowatts, with leading companies like CATL and BYD holding a 65.5% market share in the global power battery market [4] - Solid-state battery technology has achieved mass production breakthroughs, with energy density exceeding 400 Wh/kg [4] Group 4: Healthcare Sector - The healthcare market is expanding due to aging population and rising health consumption demands, with government spending in the sector reaching 2.03 trillion yuan in 2024 [5] - AI-assisted diagnosis, gene editing, and telemedicine technologies are accelerating breakthroughs and applications in the industry [5] - Leading companies like WuXi AppTec and Mindray are actively pursuing globalization strategies to capture high-end medical equipment and biopharmaceutical markets [5] Group 5: Financial and Consumer Trends - The total assets of China's financial institutions reached 495.59 trillion yuan in 2024, growing by 7.5% year-on-year [6] - The banking sector's total assets were 444.57 trillion yuan, with a growth rate of 6.5% [6] - The rise of new retail and domestic brands is reshaping the consumer market, with companies like Luckin Coffee and Pop Mart leveraging data-driven strategies [6] Group 6: Emerging and Future Industries - Emerging industries such as new energy, aerospace, and quantum technology are driving economic growth and international competitiveness [7] - The low-altitude economy is projected to reach a market size of 1.5 trillion yuan by 2025 and 3.5 trillion yuan by 2035 [7] - The embodied intelligence market is expected to exceed 480 billion yuan in 2024, with potential to surpass one trillion yuan by 2031 [7] Group 7: Super CEO Recognition - The "Super CEO" list highlights leaders across various sectors, including healthcare, new energy, entertainment, and technology, showcasing their exceptional leadership and performance [8] - These CEOs have demonstrated resilience and strategic vision in navigating industry challenges and driving company growth [8]

Core Insights - The blood oxygen monitor industry in China is experiencing strong growth driven by the increasing prevalence of chronic respiratory and cardiovascular diseases, particularly due to the aging population, which has led to a significant rise in demand for long-term blood oxygen monitoring [1][9] - The market size of the blood oxygen monitor industry in China is projected to grow from 3.8 billion yuan in 2019 to 4.5 billion yuan in 2024, with a compound annual growth rate (CAGR) of 3.44%. By 2030, the market size is expected to exceed 8 billion yuan, indicating a promising future for the industry [1][9] - The rapid adoption of telemedicine and the general increase in public health awareness are facilitating the transition of blood oxygen monitors from professional medical settings to home care and chronic disease management [1][9] Industry Overview - Blood oxygen monitors are medical devices used to measure vital indicators such as blood oxygen saturation and heart rate, with common types including fingertip, wrist, tabletop, handheld, and wearable monitors [3] - The industry has evolved significantly since the mid-1990s, transitioning from professional medical use to home and mobile applications, with advancements in technology enabling features like data collection and remote monitoring [3] Industry Policies - Blood oxygen monitors are classified as Class II medical devices under the Medical Device Supervision and Administration Regulations, requiring strict management to ensure safety and effectiveness [4] - Recent government policies aim to enhance the development of the blood oxygen monitor industry, including measures for intellectual property protection and subsidies for consumers purchasing medical devices [4] Market Dynamics - The aging population in China is a key driver for the demand for blood oxygen monitors, with the number of individuals aged 60 and above expected to reach 31.03 million by the end of 2024, accounting for 22% of the total population [5] - The blood oxygen monitor industry is supported by a robust supply chain, including raw materials, manufacturing, and sales channels, with both online and offline distribution methods [5][6] Competitive Landscape - The global blood oxygen monitor market is characterized by a mix of established international players and emerging domestic brands, with companies like Masimo Corporation and Philips leading in high-end medical-grade monitors [10][11] - Chinese companies such as Yuyue Medical and Kangtai Medical are gaining market share by offering competitive products in the mid to low-end segments, with a focus on quality and performance [10][11] Future Trends - The blood oxygen monitor industry is expected to see advancements in smart technology, enabling continuous data collection and personalized health management [14] - The trend towards portability will drive the development of smaller, lighter devices that integrate with wearable technology, enhancing user convenience [15] - The application scenarios for blood oxygen monitors are expanding beyond traditional medical settings to include fitness, high-altitude travel, and workplace health management [16]